A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of Surface Antigen, Inactivated, Influenza Vaccine, Formulation 2009-2010, When Administered to Non-Elderly Adult and Elderly Subjects.
Phase of Trial: Phase II
Latest Information Update: 18 Oct 2012
At a glance
- Drugs Influenza virus vaccine (Primary)
- Indications Influenza virus infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Novartis
- 07 Jan 2010 Actual patient number (130) added as reported by ClinicalTrials.gov.
- 07 Jan 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 23 Jun 2009 New trial record